The Size of the Asia Pacific Checkpoint Inhibitors Market is valued at USD 2.01 billion in 2019 and is projected to reach USD 7.41 billion by 2024, growing at a CAGR of 29.8% during the forecast period from 2019 to 2024.
The immune system uses checkpoints to avoid the overactivation of the immune system on normal cells. Cancer cells use these checkpoints to escape the immune system by arraying with normal cells. Checkpoint inhibitors are drugs that block these normal cells and let the immune system attack cancer cells. This is one of the treatments available in Immunotherapy.
Rising Prevalence of cancer globally, and increasing funding and government support towards developing new drugs are some of the factors driving the growth of the market. However, the high expense involved in R&D activities is one of the major factors restricting the growth of the market.
CTLA-4 Segment holds the highest share accounting for almost 94 % of the overall market. However, this segment is expected to lose some of its markets to the PD-1 inhibitors segment during the forecast period as the majority of new treatments are based on PD-1 inhibitors.
Asia Pacific Checkpoint Inhibitors Market has been segmented and sub-segmented into the following categories
On the basis of region, Asia-Pacific is the fastest-growing region because of the collaborations of international players with companies in this region.
Key Market Companies leading the Asia Pacific Checkpoint Inhibitors Market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Type
5.1.1 Introduction
5.1.2 PD-1 inhibitors
5.1.3 PD-L1 inhibitors
5.1.4 CTLA-4
5.1.5 Chimeric Antigen Receptor T-cell
5.1.6 Others
5.1.7 Y-o-Y Growth Analysis, By Drug Type
5.1.8 Market Attractiveness Analysis, By Drug Type
5.1.9 Market Share Analysis, By Drug Type
5.2 Application
5.2.1 Introduction
5.2.2 Lung cancer
5.2.3 Renal cancer
5.2.4 Blood cancer
5.2.5 Bladder Cancer
5.2.6 Hodgkin lymphoma
5.2.7 Melanoma
5.2.8 Others
5.2.9 Y-o-Y Growth Analysis, By Application
5.2.10 Market Attractiveness Analysis, By Application
5.2.11 Market Share Analysis, By Application
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Drug Type
6.1.3.3 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Drug Type
6.1.4.3 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Drug Type
6.1.5.3 By Application
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Merck & Co., Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Bristol-Myers Squibb
8.3 Roche
8.4 AstraZeneca
8.5 Ono Pharmaceutical Co., Ltd.
8.6 Juno Therapeutics
8.7 Novartis International AG
8.8 Kite Pharma
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
